Because pancreatic cancer cells express low levels of CAR (Supplementary Figures S3a and b), we constructed an RGD-modified oncolytic adenovirus carrying PKM2-targted shRNA (OAd.R.shPKM2) to investigate whether PKM2 could be a therapeutic target for pancreatic cancer (Figure 4a and Supplementary Figure S3c). Here, PKM is linked to familial pancreatic carcinoma.